|
February 1, 2007
Neurochem announcement regarding the completion of its North American Phase III clinical trial for
tramiprosate (ALZHEMED™) for the treatment of Alzheimer's disease
Neurochem Inc. (NASDAQ: NRMX; TSX: NRM) announces the completion of its 18-month North American Phase III
clinical trial for tramiprosate (ALZHEMED™) for the treatment of Alzheimer's disease (AD). This study involved
1,052 patients, at 67 clinical sites across the United States and Canada. The drop-out rate in the study was 24.8% and
791 patients were exposed to study medication for 18 months and completed their last visit, as per protocol, except
for two patients whose last study visits are anticipated next week. Neurochem is on schedule to release the top-line
results of the clinical trial in the spring of this year, as previously announced. Tramiprosate
(ALZHEMED™) is the Company's innovative investigational product candidate aimed at arresting or stopping
the progression of AD.
Neurochem's North American Phase III clinical trial is a multi-center, randomized, double-blind, placebo-controlled,
three-armed and parallel designed study. The primary objective of the clinical trial is to investigate the safety,
efficacy and disease-modifying potential of tramiprosate (ALZHEMED™) for the treatment of mild-to-moderate AD
patients. The patients were randomized to receive either placebo or one of two different dose levels (100 mg or 150 mg
twice daily) of tramiprosate (ALZHEMED™) for a period of 18 months. All participants were treated with
conventional AD therapies during the clinical trial and were required to be on a stable dose of conventional therapies
for at least four months prior to the initial screening visit. At study entry, patients in this trial were on therapies
for an average of approximately 20 months.
The primary efficacy endpoints of this study include the evaluation of cognitive abilities and a global measure of
performance utilizing ADAS-cog1 and CDR-SB scores2, respectively. If treatment efficacy is established, the disease
modification effect of tramiprosate (ALZHEMED™) will then be assessed by brain volume change from baseline
as measured by magnetic resonance imaging.
An open-label Phase III extension study was initiated in May of 2006. Approximately 90% of the patients who completed
the North American Phase III clinical trial have continued into the ongoing extension study and receive tramiprosate
ALZHEMED™).
Over the course of the Phase III study, the Data Safety Monitoring Board (DSMB) met five times and recommended in
each instance that Neurochem continue the clinical trial.
"The completion of our North American Phase III study is a major milestone in Neurochem's efforts to potentially offer
an innovative treatment for Alzheimer's disease patients and marks a very important achievement for our company,"
said Dr. Francesco Bellini, Chairman, President and CEO of Neurochem. "Our goal is to release the results of this
trial in the spring of 2007. We sincerely thank everyone who contributed to this state-of-the art trial, with a special
thanks to the patients, their families and their caregivers who agreed to participate and helped us advance a program
which could lead to a potential breakthrough treatment for AD," he concluded.
Ongoing Phase III Clinical Trial in Europe Progressing Well
Neurochem is also currently advancing a European Phase III clinical trial for tramiprosate (ALZHEMED™) for the
treatment of AD. The study in Europe is of a similar design to the North American trial and is expected to recruit
approximately 930 mild-to-moderate AD patients at more than 70 clinical centers in 10 European countries. The enrolment
is scheduled to be completed in early 2007. To date, the DSMB has met once and has recommended the continuation of this
trial.
About Tramiprosate (ALZHEMED™)
Tramiprosate (ALZHEMED™) is a small, orally-administered molecule known as an amyloid antagonist, which
crosses the blood-brain-barrier, binds to soluble Aß peptide and interferes with the amyloid cascade that
is associated with amyloid deposition and the toxic effects of Aß peptide in the brain. The presence of
amyloid in the brain is one of the major histopathological characteristics of AD. The amyloid cascade hypothesis
proposes that certain forms of Aß peptide are toxic and causally related to the severity of AD. The Aß
peptide is one of the most promising targets for the development of AD therapies.
About Alzheimer's Disease
AD is a leading cause of death in older people. The disease is characterized by the progressive death of nerve cells
in the brain, making it difficult for the brain's signals to be transmitted properly. A person with AD experiences
problems with memory, judgment, thinking, and eventually with motor functions, all of which make it difficult for
the person to participate in daily activities.
According to the National Institute on Aging's "Progress Report on Alzheimer's Disease, 2000," AD is the
most common cause of dementia among people aged 65 and older. Scientists estimate that up to four and a half million
people in the United States currently suffer with the disease and the prevalence (the number of people with the disease at
any one time) doubles every five years beyond age 65. It is estimated that approximately 360,000 new cases (incidence) will
occur each year and that this number will increase as the population ages.
In a 2000 report, the Biotechnology Industry Organization estimated that in the United States the total cost of AD is
approximately US$100 billion per year.
About Neurochem
Neurochem Inc. is focused on the development and commercialization of innovative therapeutics to address critical
unmet medical needs. Eprodisate (KIACTA™ - formerly FIBRILLEX™) is currently being developed for the
treatment of Amyloid A (AA) amyloidosis, and is under regulatory review for marketing approval by the U.S. Food
and Drug Administration and European Medicines Agency. Tramiprosate (ALZHEMED™), for the treatment of Alzheimer's
disease, has completed a Phase III clinical trial in North America and is currently in a Phase III clinical trial in
Europe, while tramiprosate (CEREBRIL™), for the prevention of Hemorrhagic Stroke caused by Cerebral Amyloid
Angiopathy, has completed a Phase IIa clinical trial.
To Contact Neurochem
For additional information on Neurochem and its drug development programs, please call the North American toll-free number
1 877 680-4500 or visit our Web Site at: www.neurochem.com.
1 Alzheimer's Disease Assessment Scale, cognitive subpart (ADAS-cog). The ADAS-cog is a 70-point scale
designed to measure, with the use of questionnaires, the progression and the severity of cognitive decline as seen
in AD.
2 Clinical Dementia Rating - Sum of Boxes rating scale (CDR-SB), a measure of global performance.
This news release contains forward-looking statements regarding tramiprosate (ALZHEMED™) as well as regarding
continuing and further development efforts. These statements are based on the current analysis and expectations of
management. Drug development necessarily involves numerous risks and uncertainties, which could cause actual results to
differ materially from this current analysis and these expectations. Analysis regarding the results of clinical trials
may not provide definitive results regarding safety, tolerability or therapeutic benefits. Even if all the endpoints
sought in the clinical trials were met (which is not certain), there is no certainty that regulators would ultimately
approve tramiprosate (ALZHEMED™) for sale to the public. Risks and uncertainties may include: failure to demonstrate
the safety, tolerability and efficacy of our product, the expense and uncertainty of obtaining regulatory approval,
including from the FDA, and the possibility of having to conduct additional clinical trials. Further, even if regulatory
approval is obtained, therapeutic products are generally subject to: stringent on-going governmental regulation,
challenges in gaining market acceptance, and competition. Neurochem does not undertake any obligation to publicly
update its forward-looking statements, whether as a result of new information, future events, or otherwise. Please see
the Annual Information Form for further risk factors that might affect the Company and its business.
For further Information, please contact:
Dr. Lise Hébert
Vice President, Corporate Communications
lhebert@neurochem.com
275 Armand-Frappier
Laval (Quebec)
H7V 4A7
Tel: (450) 680-4500
Fax: (450) 680-4501
|
|
